Business Wire

Seven2 and HRK LUNIS Announce Successful Double Closing

17.9.2025 10:01:00 CEST | Business Wire | Press Release

Share

Seven2, a leading European private equity firm, and HRK LUNIS, one of the leading independent wealth managers in Germany, have successfully completed both the majority stake acquisition of HRK LUNIS by Seven2, announced in March of this year, and the merger with Grossbötzl, Schmitz & Partner, announced in April. The smooth approval process is a positive sign for the German wealth management market and underlines the stability of the sector. With the completed double closing, HRK LUNIS's client assets under management have increased to approximately €7.5 billion and the number of employees to 120.

The acquisition of HRK LUNIS is Seven2’s first investment in Germany, marking a key strategic milestone to further expand the private equity firm's position in Europe. Together with Seven2, HRK LUNIS will continue its growth trajectory, further develop its product offering, and optimize its digital capabilities to drive maximum customer benefits. The company offers a broad and competitive range of services, including discretionary wealth management, advisory, institutional asset management and fund management, private equity, and family office services (through its multi-family office WERTIQ). It operates on a fully integrated platform with a central investment office and a common IT infrastructure.

The merger with Grossbötzl, Schmitz & Partner also underscores HRK LUNIS's active acquisition strategy and strengthens its regional presence. The merger with the renowned and long-established wealth manager is a further active contribution to the necessary consolidation of the still fragmented market of independent wealth managers. Both transactions, whose closing was originally expected in Q4 2025 and Q1 2026 respectively, were completed faster than planned after all necessary regulatory approvals were granted.

Andreas Brandt, CEO and co-founder of HRK LUNIS, who retains a significant ownership stake in the company, is pleased with the smooth handling of the double closing: “With Seven2 as our partner, we are perfectly positioned to drive our planned organic and inorganic growth and to consolidate and expand our position as a leading independent wealth manager in the DACH region. The merger with Grossbötzl, Schmitz & Partner is also an important strategic step to strengthen our presence in North Rhine-Westphalia and to actively shape the consolidation of the market.”

Dr. Florian Wolff, Partner at Seven2 and Head of the DACH Region, adds: “As our first acquisition in Germany, the merger of HRK LUNIS is a key strategic milestone for us. We are open to further external growth steps with independent financial service providers or advisory teams in the DACH region. Together, we want to further develop the company's profile, expand the product offering - including alternative investments - and optimize digital capabilities to create maximum value for clients.”

The financial details of the transactions were not disclosed.

About HRK LUNIS

With assets under management of approximately €7.5 billion, HRK LUNIS is one of the largest independent wealth managers in the German-speaking region. 120 employees handle the needs of sophisticated private clients, entrepreneurs, and their families. In the institutional sector and fund management, the company is responsible for the assets of companies, foundations, associations, and pension funds. HRK LUNIS distinguishes itself from competitors primarily through its in-house investment office with 19 trained analysts and fund managers. The expertise in private equity, which has grown over more than 20 years, is another unique selling proposition. The offering is complemented by the independently operating multi-family office WERTIQ. The wholly owned subsidiary of HRK LUNIS offers clients individual added value that goes beyond purely financial matters. The focus is on strategic asset planning, overall wealth controlling, digital financial accounting, as well as retirement and generational planning, and foundation management. In-house real estate experts assist with topics such as real estate acquisition or sale. The Munich-based company also conducts beauty contests for private, institutional, and sustainable wealth management mandates. More information can be found at www.hrklunis.de

About Seven2

Seven2 is an independent European private equity firm that is fully owned by its partners and finances SMEs and midcaps across Europe. It invests in high-potential companies in its main sectors of specialization: Tech & Telecom and Services. Seven2 empowers entrepreneurs with the expertise, practical support, and investment they need to achieve long-lasting sustainable growth. Seven2, formerly Apax Partners SAS, is headquartered in Paris and has offices in Milan, Amsterdam, and Munich.

Follow us: www.seven2.eu | Seven2 | @seven2_pe

View source version on businesswire.com: https://www.businesswire.com/news/home/20250917496873/en/

Contacts

Press Contacts
HRK LUNIS - Joachim Spiering
Head of Press and Public Relations
+49 89 21 66 86 56
joachim.spiering@hrklunis.de

Seven2 - Lauren Bardet
Communications director
+33 6 16 32 72 82
lauren.bardet@seven2.eu

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye